Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura E Johnson

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|June 28, 2014
Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patientsCarol L Moore, Anatole Besarab, Marie Ajluni, et al.
Journal for Immunotherapy of Cancer|March 12, 2022
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)Douglas G McNeel, Jens C Eickhoff, Ellen Wargowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancerDouglas G McNeel, Jordan T Becker, Jens C Eickhoff, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United StatesYoon Soo Park, Jennifer M Adams-Haduch, Kathleen A Shutt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2019
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate CancerDouglas G McNeel, Jens C Eickhoff, Laura E Johnson, et al.
Cancers|October 3, 2020
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)Melissa Gamat-Huber, Donghwan Jeon, Laura E Johnson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 7, 2011
Botulism toxemia following laparoscopic appendectomySusan C Nystrom, Eden V Wells, Hiren S Pokharna, et al.
The Prostate|February 10, 2017
Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD)Brian M Olson, Eric S Bradley, Thomas Sawicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancerDouglas G McNeel, Edward J Dunphy, James G Davies, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2012
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United StatesYohei Doi, Yoon Soo Park, Jesabel I Rivera, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Clinical Journal of the American Society of Nephrology : CJASN|June 28, 2014
Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patientsCarol L Moore, Anatole Besarab, Marie Ajluni, et al.
Journal for Immunotherapy of Cancer|March 12, 2022
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)Douglas G McNeel, Jens C Eickhoff, Ellen Wargowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancerDouglas G McNeel, Jordan T Becker, Jens C Eickhoff, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United StatesYoon Soo Park, Jennifer M Adams-Haduch, Kathleen A Shutt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2019
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate CancerDouglas G McNeel, Jens C Eickhoff, Laura E Johnson, et al.
Cancers|October 3, 2020
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)Melissa Gamat-Huber, Donghwan Jeon, Laura E Johnson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 7, 2011
Botulism toxemia following laparoscopic appendectomySusan C Nystrom, Eden V Wells, Hiren S Pokharna, et al.
The Prostate|February 10, 2017
Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD)Brian M Olson, Eric S Bradley, Thomas Sawicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancerDouglas G McNeel, Edward J Dunphy, James G Davies, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2012
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United StatesYohei Doi, Yoon Soo Park, Jesabel I Rivera, et al.
Pageof 5